Microscopic photo from National Cancer Institute

Sector group

Life sciences

HGF’s life sciences attorneys understand the challenges associated with commercially focused IP management and can advise on the pertinent issues, from invention conception through to patent term extension, to maximise the value of intellectual property.

Lady looking into test tube

As one of Europe’s largest groups of specialist life science attorneys, HGF has the wealth of technical and legal expertise to deliver truly global, commercially-focused strategies.

From protecting new research from Europe’s most prestigious universities, to high-profile oppositions for international healthcare companies on market-leading technologies, the team possesses in-depth legal experience. Particular technical expertise within the group covers the fields of food technology, microbiome for therapeutic purposes, cell and gene therapy, bioinformatics, cleantech, AgBio, immunobiology, gene editing technologies, personalised medicine, bioprocessing and anti-infectives.

In addition, our life sciences attorneys work closely with our IP lawyers in relation to life cycle agreements such as MTAs, R&D collaborations, companion diagnostics, IP licensing, clinical trials through to commercial manufacturing and supply, and litigation.

Latest updates

Prominence given to the preservation of the status quo

The Court of Appeal has stayed an interim injunction to allow Mylan’s generic to remain on the market in a bid to preserve the status quo, despite recognising that damages …

Read article

Managing Intellectual Property IP Stars 2022

After months of research, Managing IP has published the IP Stars list for 2022. HGF is delighted to have 16 attorneys from England, Scotland, Ireland, Netherlands and Germany recognised and …

Read article

Managing IP EMEA Awards 2022: HGF shortlisted for 11 awards

We are delighted to announce that HGF is shortlisted for 11 awards at the upcoming Managing IP EMEA Awards 2022: European European Firm of the Year – Patent Contentious (Patent …

Read article

Celebrating 3 years with In2Science UK

We are excited to mark and celebrate our 3-year partnership with award winning charity In2Science UK. Our partnership has gone from strength to strength, and we are delighted to confirm …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article

Ed Sheeran successfully defends hit song 'Shape Of You' against High Court copyright infringement claim

The UK musician, Ed Sheeran, one of the world’s best selling artists with sales of 26 million albums and 100 million singles worldwide, has successfully defended a claim brought against …

Read article

Extension to oral proceedings by videoconference in opposition proceedings

The pilot project for oral proceedings held by videoconference (VICO) in opposition cases has been further extended to 31 December 2022. This is due to ongoing safety concerns about the …

Read article

Update on the UPC - expected timeline

The first meetings of the UPC Administrative, Budget and Advisory Committee took place at the end of February. Following these, the Advisory Committee have begun interviewing judges for the court …

Read article